Rare Diseases
An Introduction to Rare Diseases
Rare respiratory conditions encompass a spectrum of pulmonary disorders that affect a limited number of individuals, often presenting significant challenges due to their scarcity and complexity. These conditions, including interstitial lung diseases, pulmonary vascular disorders, and rare genetic respiratory disorders, pose unique diagnostic and therapeutic challenges.
Current treatments for these conditions often involve symptom management and supportive care, but the evolving landscape of pulmonary medicine is witnessing promising advancements. Emerging therapies, including precision medicine approaches and targeted treatments, are offering new avenues for managing these conditions.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
CLEAN-PCD is a phase 2 randomized, double-blind, placebo-controlled crossover trial investigating the efficacy and safety of idrevloride in primary ciliary dyskinesia (PCD). It was a pleasure to talk with Dr. Thomas Ferkol (UNC Department of Pediatrics, Chapel Hill, NC, USA) around ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
